Komorbidität: Anämie und Herzinsuffizienz

Schlüsselwörter

Anämie - Herzinsuffizienz

Keywords

anemia - heart failure

Literatur

• 1 Al-Ahmad A, Rand W M, Manjunath G. et al . Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction.  J Am Coll Cardiol. 2001;  38 (4) 955-962
• 2 Albitar S, Genin R, Fen-Chong M, Serveaux M O, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients.  Nephrol Dial Transplant. 1998;  13 (5) 1206-1210
• 3 Anand I, McMurray J J, Whitmore J. et al . Anemia and its relationship to clinical outcome in heart failure.  Circulation. 2004;  110 (2) 149-154
• 4 Anand I S, Kuskowski M A, Rector T S. et al . Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.  Circulation. 2005;  112 (8) 1121-1127
• 5 Androne A S, Katz S D, Lund L. et al . Hemodilution is common in patients with advanced heart failure.  Circulation. 2003;  107 (2) 226-229
• 6 Anker S D, Chua T P, Ponikowski P. et al . Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia.  Circulation. 1997;  96 (2) 526-534
• 7 Anker S D, Haehling S. Inflammatory mediators in chronic heart failure: an overview.  Heart. 2004;  90 (4) 464-470
• 8 Bennett C L, Silver S M, Djulbegovic B. et al . Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.  JAMA. 2008;  299 (8) 914-924
• 9 Besarab A, Soman S. Anemia management in chronic heart failure: lessons learnt from chronic kidney disease.  Kidney Blood Press Res. 2005;  28 (5 – 6) 363-371
• 10 Bolger A P, Bartlett F R, Penston H S. et al . Intravenous iron alone for the treatment of anemia in patients with chronic heart failure.  J Am Coll Cardiol. 2006;  48 (6) 1225-1227
• 11 Deswal A, Petersen N J, Feldman A M, Young J B, White B G, Mann D L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).  Circulation. 2001;  103 (16) 2055-2059
• 12 Drueke T B, Locatelli F, Clyne N. et al . Normalization of hemoglobin level in patients with chronic kidney disease and anemia.  N Engl J Med. 2006;  355 (20) 2071-2084
• 13 Ezekowitz J A, McAlister F A, Armstrong P W. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure.  Circulation. 2003;  107 (2) 223-225
• 14 Felker G M, Gattis W A, Leimberger J D. et al . Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure.  Am J Cardiol. 2003;  92 (5) 625-628
• 15 George J, Patal S, Wexler D. et al . Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers.  Arch Intern Med. 2005;  165 (11) 1304-1309
• 16 Gibbs C R, Blann A D, Watson R D, Lip G Y. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy.  Circulation. 2001;  103 (13) 1746-1751
• 17 Go A S, Yang J, Ackerson L M. et al . Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.  Circulation. 2006;  113 (23) 2713-2723
• 18 Griffith G C, Stragnell R, Levinson D C, Moore F J, Ware A G. A study of the beneficial effects of anticoagulant therapy in congestive heart failure.  Ann Intern Med. 1952;  37 (5) 867-887
• 19 Hoppe U C. Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists?.  Clin Res Cardiol. 2007;  96 (4) 196-198
• 20 Horwich T B, Fonarow G C, Hamilton M A, MacLellan W R, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure.  J Am Coll Cardiol. 2002;  39 (11) 1780-1786
• 21 Kalra P R, Bolger A P, Francis D P. et al . Effect of anemia on exercise tolerance in chronic heart failure in men.  Am J Cardiol. 2003;  91 (7) 888-891
• 22 Kazory A, Ross E A. Anemia: the point of convergence or divergence for kidney disease and heart failure?.  J Am Coll Cardiol. 2009;  53 (8) 639-647
• 23 Komajda M. Prevalence of anemia in patients with chronic heart failure and their clinical characteristics.  J Card Fail. 2004;  10 (1 Suppl) S1-S4
• 24 Kosiborod M, Smith G L, Radford M J, Foody J M, Krumholz H M. The prognostic importance of anemia in patients with heart failure.  Am J Med. 2003;  114 (2) 112-119
• 25 Levine B, Kalman J, Mayer L, Fillit H M, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.  N Engl J Med. 1990;  323 (4) 236-241
• 26 Lipton A J, Johnson M A, Macdonald T, Lieberman M W, Gozal D, Gaston B. S-nitrosothiols signal the ventilatory response to hypoxia.  Nature. 2001;  413 (6852) 171-174
• 27 Maggioni A P, Opasich C, Anand I. et al . Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice.  J Card Fail. 2005;  11 (2) 91-98
• 28 Mancini D M, Katz S D, Lang C C, LaManca J, Hudaihed A, Androne A S. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure.  Circulation. 2003;  107 (2) 294-299
• 29 Mitchell J E. Emerging role of anemia in heart failure.  Am J Cardiol. 2007;  99 (6B) 15D-20D
• 30 Mozaffarian D, Nye R, Levy W C. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE).  J Am Coll Cardiol. 2003;  41 (11) 1933-1939
• 31 Murphy C L, McMurray J J. Approaches to the treatment of anaemia in patients with chronic heart failure.  Heart Fail Rev. 2008;  13 (4) 431-438
• 32 Naito M, Kawashima A, Akiba T, Takanashi M, Nihei H. Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients.  Am J Nephrol. 2003;  23 (5) 287-293
• 33 Nanas J N, Matsouka C, Karageorgopoulos D. et al . Etiology of anemia in patients with advanced heart failure.  J Am Coll Cardiol. 2006;  48 (12) 2485-2489
• 34 Nixon J V. Left ventricular mural thrombus.  Arch Intern Med. 1983;  143 (8) 1567-1571
• 35 Okonko D O, Grzeslo A, Witkowski T. et al . Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.  J Am Coll Cardiol. 2008;  51 (2) 103-112
• 36 Ponikowski P, Anker S D, Szachniewicz J. et al . Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.  J Am Coll Cardiol. 2007;  49 (7) 753-762
• 37 Ronco C, Haapio M, House A A, Anavekar N, Bellomo R. Cardiorenal syndrome.  J Am Coll Cardiol. 2008;  52 (19) 1527-1539
• 38 Schwengel R H, Gottlieb S S, Fisher M L. Protein-energy malnutrition in patients with ischemic and nonischemic dilated cardiomyopathy and congestive heart failure.  Am J Cardiol. 1994;  73 (12) 908-910
• 39 Sharma R, Francis D P, Pitt B, Poole-Wilson P A, Coats A J, Anker S D. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial.  Eur Heart J. 2004;  25 (12) 1021-1028
• 40 Silverberg D S, Wexler D, Blum M. et al . The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations.  J Am Coll Cardiol. 2000;  35 (7) 1737-1744
• 41 Silverberg D S, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia.  Semin Nephrol. 2006;  26 (4) 296-306
• 42 Silverberg D S, Wexler D, Sheps D. et al . The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study.  J Am Coll Cardiol. 2001;  37 (7) 1775-1780
• 43 Singh A K, Szczech L, Tang K L. et al . Correction of anemia with epoetin alfa in chronic kidney disease.  N Engl J Med. 2006;  355 (20) 2085-2098
• 44 Smilde T D, Damman K HP. et al . Differential associations between renal function and „modifiable” risk factors in patients with chronic heart failure.  Clin Res Cardiol. 2009;  98 (2) 121-129
• 45 Szachniewicz J, Petruk-Kowalczyk J, Majda J. et al . Anaemia is an independent predictor of poor outcome in patients with chronic heart failure.  Int J Cardiol. 2003;  90 (2 – 3) 303-308
• 46 Tang Y D, Katz S D. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options.  Circulation. 2006;  113 (20) 2454-2461
• 47 Tanner H, Moschovitis G, Kuster G M. et al . The prevalence of anemia in chronic heart failure.  Int J Cardiol. 2002;  86 (1) 115-121
• 48 van der Meer, Voors A A, Lipsic E, Smilde T D, van Gilst W H, van Veldhuisen D J. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure.  J Am Coll Cardiol. 2004;  44 (1) 63-67
• 49 van Veldhuisen D J, Dickstein K, Cohen-Solal A. et al . Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.  Eur Heart J. 2007;  28 (18) 2208-2216
• 50 Weil J, Colin-Jones D, Langman M. et al . Prophylactic aspirin and risk of peptic ulcer bleeding.  BMJ. 1995;  310 (6983) 827-830